Innate Pharma SA
IPHA1.790USD
+0.040+2.29%
Close 12/22, 16:00（ET）Quotes delayed by 15 min
164.96MMarket Cap
LossP/E TTM
More Details of Innate Pharma SA Company
Innate Pharma SA is a France-based biopharmaceutical company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. It works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. It also has a multi-product partnership with AstraZeneca.
Innate Pharma SA Info
Ticker SymbolIPHA
Company nameInnate Pharma SA
IPO dateOct 31, 2006
CEODickinson (Jonathan Elliot)
Number of employees181
Security typeDepository Receipt
Fiscal year-endOct 31
Address117 avenue de Luminy
CityMARSEILLE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryFrance
Postal code13009
Phone33430303030
Websitehttps://www.innate-pharma.com/
Ticker SymbolIPHA
IPO dateOct 31, 2006
CEODickinson (Jonathan Elliot)
Company Executives of Innate Pharma SA
Name
Name/Position
Position
Shareholding
Change
Prof. Eric Vivier, Ph.D.
Prof. Eric Vivier, Ph.D.
Senior Vice President, Chief Scientific Officer, Member of the Leadership Team
Senior Vice President, Chief Scientific Officer, Member of the Leadership Team
--
--
Mr. Nicola Beltraminelli
Mr. Nicola Beltraminelli
Vice President, Chief Development Officer, Member of the Leadership Team
Vice President, Chief Development Officer, Member of the Leadership Team
--
--
Mr. Frederic Lombard
Mr. Frederic Lombard
Chief Financial Officer, Member of the Leadership Team
Chief Financial Officer, Member of the Leadership Team
--
--
Mr. Gilles Brisson
Mr. Gilles Brisson
Member of the Supervisory Board
Member of the Supervisory Board
--
--
Mr. Henry Wheeler
Mr. Henry Wheeler
Vice President - Investor Relations and Communications, Member of the Leadership Team
Vice President - Investor Relations and Communications, Member of the Leadership Team
--
--
Ms. Odile Belzunce
Ms. Odile Belzunce
Vice President - Compliance, IT and Portfolio Management, Member of the Leadership Team
Vice President - Compliance, IT and Portfolio Management, Member of the Leadership Team
--
--
Mr. Olivier Martinez
Mr. Olivier Martinez
Member of the Supervisory Board, Representative of Bpifrance Participations
Member of the Supervisory Board, Representative of Bpifrance Participations
--
--
Ms. Claire De Saint-blanquat
Ms. Claire De Saint-blanquat
Vice President - Legal and Corporate Affairs, Secretary of the Supervisory Board, Member of the Leadership Team
Vice President - Legal and Corporate Affairs, Secretary of the Supervisory Board, Member of the Leadership Team
--
--
Dr. Sally Bennett
Dr. Sally Bennett
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Ms. Veronique Chabernaud, M.D.
Ms. Veronique Chabernaud, M.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Prof. Eric Vivier, Ph.D.
Prof. Eric Vivier, Ph.D.
Senior Vice President, Chief Scientific Officer, Member of the Leadership Team
Senior Vice President, Chief Scientific Officer, Member of the Leadership Team
--
--
Mr. Nicola Beltraminelli
Mr. Nicola Beltraminelli
Vice President, Chief Development Officer, Member of the Leadership Team
Vice President, Chief Development Officer, Member of the Leadership Team
--
--
Mr. Frederic Lombard
Mr. Frederic Lombard
Chief Financial Officer, Member of the Leadership Team
Chief Financial Officer, Member of the Leadership Team
--
--
Mr. Gilles Brisson
Mr. Gilles Brisson
Member of the Supervisory Board
Member of the Supervisory Board
--
--
Mr. Henry Wheeler
Mr. Henry Wheeler
Vice President - Investor Relations and Communications, Member of the Leadership Team
Vice President - Investor Relations and Communications, Member of the Leadership Team
--
--
Ms. Odile Belzunce
Ms. Odile Belzunce
Vice President - Compliance, IT and Portfolio Management, Member of the Leadership Team
Vice President - Compliance, IT and Portfolio Management, Member of the Leadership Team
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
AllianceBernstein L.P.
0.07%
Morgan Stanley & Co. International Plc
0.05%
Citadel Advisors LLC
0.02%
Other
99.86%
Shareholders
Shareholders
Proportion
AllianceBernstein L.P.
0.07%
Morgan Stanley & Co. International Plc
0.05%
Citadel Advisors LLC
0.02%
Other
99.86%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
0.07%
Research Firm
0.05%
Hedge Fund
0.02%
Investment Advisor
0.01%
Other
99.85%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
19
159.42K
0.17%
-86.46K
2025Q2
17
157.41K
0.17%
-54.22K
2025Q1
22
261.37K
0.29%
-22.81K
2024Q4
23
278.64K
0.34%
-188.16K
2024Q3
25
406.53K
0.50%
-579.77K
2024Q2
27
405.72K
0.50%
-529.94K
2024Q1
29
344.92K
0.22%
-517.69K
2023Q4
32
202.70K
0.25%
-1.13M
2023Q3
36
377.53K
0.47%
-1.02M
2023Q2
36
293.58K
0.36%
-1.21M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
AllianceBernstein L.P.
60.75K
0.07%
+36.48K
+150.33%
Jun 30, 2024
Morgan Stanley & Co. International Plc
51.22K
0.06%
+7.70K
+17.69%
Jun 30, 2025
Citadel Advisors LLC
26.62K
0.03%
+2.35K
+9.68%
Jun 30, 2025
UBS Financial Services, Inc.
5.96K
0.01%
-3.04K
-33.82%
Jun 30, 2025
GAMMA Investing LLC
2.28K
0%
-1.18K
-34.00%
Sep 30, 2025
Rhumbline Advisers Ltd. Partnership
470.00
0%
-205.00
-30.37%
Jun 30, 2025
Barclays Bank PLC
307.00
0%
--
--
Jun 30, 2025
Optiver Holding B.V.
101.00
0%
--
--
Jun 30, 2025
Tower Research Capital LLC
--
0%
-3.00
-100.00%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
ActivePassive International Equity ETF
0%
DFA Dimensional Intl Sustainability Core 1 ETF
0%
ActivePassive International Equity ETF
Proportion0%
DFA Dimensional Intl Sustainability Core 1 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Innate Pharma SA?
The top five shareholders of Innate Pharma SA are:
AllianceBernstein L.P. holds 60.75K shares, accounting for 0.07% of the total shares.
Morgan Stanley & Co. International Plc holds 51.22K shares, accounting for 0.06% of the total shares.
Citadel Advisors LLC holds 26.62K shares, accounting for 0.03% of the total shares.
UBS Financial Services, Inc. holds 5.96K shares, accounting for 0.01% of the total shares.
GAMMA Investing LLC holds 2.28K shares, accounting for 0.00% of the total shares.
AllianceBernstein L.P. holds 60.75K shares, accounting for 0.07% of the total shares.
Morgan Stanley & Co. International Plc holds 51.22K shares, accounting for 0.06% of the total shares.
Citadel Advisors LLC holds 26.62K shares, accounting for 0.03% of the total shares.
UBS Financial Services, Inc. holds 5.96K shares, accounting for 0.01% of the total shares.
GAMMA Investing LLC holds 2.28K shares, accounting for 0.00% of the total shares.
What are the top three shareholder types of Innate Pharma SA?
The top three shareholder types of Innate Pharma SA are:
AllianceBernstein L.P.
Morgan Stanley & Co. International Plc
Citadel Advisors LLC
AllianceBernstein L.P.
Morgan Stanley & Co. International Plc
Citadel Advisors LLC
How many institutions hold shares of Innate Pharma SA (IPHA)?
As of 2025Q3, 19 institutions hold shares of Innate Pharma SA, with a combined market value of approximately 159.42K, accounting for 0.17% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 0.00%.
What is the biggest source of revenue for Innate Pharma SA?
In --, the -- business generated the highest revenue for Innate Pharma SA, amounting to -- and accounting for --% of total revenue.
